210644-62-5

Basic information

• Product Name: SU 6668
• Synonyms: SU 6668;3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid;1H-Pyrrole-3-propanoic acid, 5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-;5-((Z)-1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid;PDGFR Tyrosine Kinase Inhibitor VI, SU6668;3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoicacid
• CAS NO: 210644-62-5
• Molecular Formula: C18H18N2O3
• Molecular Weight: 310.36
• Mol File: 210644-62-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 590.5°Cat760mmHg
• Flash Point: 310.9°C
• Appearance: /
• Density: 1.328g/cm³
• Vapor Pressure: 8.68E-15mmHg at 25°C
• Refractive Index: 1.674
• Storage Temp.: +2C to +8C
• CAS DataBase Reference: SU 6668(CAS DataBase Reference)
• NIST Chemistry Reference: SU 6668(210644-62-5)
• EPA Substance Registry System: SU 6668(210644-62-5)

Safety Data

• Hazardous Substances Data: 210644-62-5(Hazardous Substances Data)

Usage

Uses

PDGFR Tyrosine Kinase Inhibitor VI, SU6668 is a potent ATP-competitive inhibitor against tyrosine kinases.

General Description

A cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 μM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 μM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 μM, respectively).

InChI:InChI=1/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-

Upstream product

• 13219-76-6 4-<2-(methoxycarbonyl)ethyl>-3,5-dimethylpyrrole-2-carboxylic acid 
• 17266-65-8 ethyl 4,6-dioxo-5-methylheptanoate 
• 54474-50-9 2,4-dimethyl-3-pyrrolepropanoic acid 
• 54278-10-3 ethyl 5-(ethoxycarbonyl)-2,4-dimethyl-1H-pyrrole-3-propanoate 
• 54474-51-0 methyl 2,4-dimethyl-3-pyrrolepropionate 
• 20303-31-5 benzyl 4-(2-methoxycarbonylethyl)-3,5-dimethylpyrrole-2-carboxylate 
• 18818-25-2 methyl 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)propanoate 
• 16132-20-0 tert-butyl 3,5-dimethyl-4-(2-methoxycarbonylethyl)-1H-pyrrole-2-carboxylate 
• 123-75-1 pyrrolidine 
• 59-48-3 2-oxoindole 
• 1133-96-6 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)-propionic acid 

Relevant articles and documents

DIHYDROINDOLE DERIVATIVES USEFUL IN PARKINSON'S DISEASE

The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis

The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis,

Pyrrole substituted 2-indolinone protein kinase inhibitors

The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.